Endometrial thickness: individual and mean growth profiles for different hormone replacement regimens.
Currently, there is a paucity of data describing endometrial growth, with most studies concentrating on endometrial thickness immediately prior to implantation or embryo transfer. This study looked at the individual and combined growth profiles of 67 volunteers receiving three different hormone replacement regimens. Each treatment regimen was in excess of that considered necessary for optimal growth, and all promoted an endometrial thickness that would be considered satisfactory for embryo transfer. Three patterns of growth were identified, but overall there was a decrease in the rate of endometrial growth with duration of treatment. As expected, analysis of variance did not show a significant difference between the mean growth profiles for the three hormone replacement regimens. The correlation (r = 0.45, P < 0.0001) between rank order on day 3 and day 10 of treatment indicates that interim analysis during early treatment cannot accurately predict later thickness, but a doubling of endometrial thickness can be expected in most cases. A relationship between endometrial thickness and either the treatment dose or serum concentrations of oestradiol was not found. These findings suggest that manipulation of endometrial growth is not possible by adjustment of either the treatment dose or serum concentration. The findings indicate that treatment beyond 12 days does not promote either a clinically significant increase in endometrial thickness of an excessive thickness, suggesting that maintenance of an oocyte recipient in a pseudo-follicular phase is unlikely to be disadvantageous to implantation.
Brooks
A A
AA
Academic Department of Obstetrics and Gynaecology, Chelsea and Westminster Hospital, London, UK.
Johnson
M R
MR
Pawson
M E
ME
Thomas
A
A
Phelan
L K
LK
Abdalla
H I
HI
D000328:Adult; D002064:Buserelin / Q000008:administration & dosage; D010064:Embryo Implantation; D004717:Endometrium / Q000033:anatomy & histology* / Q000254:growth & development*; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D011374:Progesterone / Q000008:administration & dosage*
D011374:Progesterone; D004958:Estradiol; D002064:Buserelin